Upstream Bio Reports P-II VALIANT Data for Verekitug in Severe Asthma

Shots: Upstream Bio presented results from the P-II VALIANT study evaluating verekitug in 478 adults with severe asthma, with the study meeting its 1EP of reducing the annualized asthma exacerbation rate (AAER) across all dose regimens. Verekitug 100 mg dosed every 12 wks. reduced AAER by 56% vs. PBO (p<0.001) and also improved lung function…

ByPrince GiriSeptember 8, 2026

Rezubio Reports First Cohort Dosing in P-I Trial of RZ-520 Following FDA and NMPA IND Clearances

Shots: Rezubio has completed dosing of the first cohort in its P-I trial of RZ-520, following US FDA & Chinese NMPA clearances to assess its safety, tolerability, PK & PD in healthy volunteers RZ-520 is a clinical-stage asset developed using Rezubio’s MADD platform, with preclinical studies showing robust efficacy, superior safety & negligible systemic exposure…

ByRidhi RastogiSeptember 7, 2026

Moderna Reports the EC Approval of mCOMBRIAX to Protect Against Influenza and COVID-19

Shots: The EC has approved mCOMBRIAX (mRNA-1083), a combination vaccine for the prevention of influenza and COVID-19 in patients ≥50 yrs. across all 30 EEA states Approval was based on a P-III trial evaluating mRNA-1083 in ~8,000 adults across two cohorts: ≥65yrs (n~4,000) vs co-administered Fluzone / Efluelda (a high dose influenza vaccine )+ Spikevax and 50–64yrs (n~4,000) vs Fluarix + Spikevax, where all 1EPs were met, demonstrating non-inferiority of immune response with acceptable safety and tolerability MRNA-1010, Moderna’s…

ByDipanshu DixitApril 20, 2026

Upstream Bio Reports P-II VALIANT Data for Verekitug in Severe Asthma

Rezubio Reports First Cohort Dosing in P-I Trial of RZ-520 Following FDA and NMPA IND Clearances

Moderna Reports the EC Approval of mCOMBRIAX to Protect Against Influenza and COVID-19

Contact US

FOLLOW US